In this clip from The Motley Fool's Industry Focus: Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss how Regenxbio's proprietary viral vectors could present investors with an opportunity to profit from treatments for spinal muscular atrophy and wet age-related macular degeneration, two blockbuster indications.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,